Jim Simons
ABCL icon

Jim Simons’s AbCellera Biologics ABCL Stock Holding History

Jim Simons’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.27M Sell
1,510,629
-878,600
-37% -$3.16M 0.01% 1350
2025
Q4 		$8.17M Sell
2,389,229
-971,500
-29% -$4.34M 0.01% 1021
2025
Q3 		$16.9M Buy
3,360,729
+53,300
+2% +$235K 0.02% 811
2025
Q2 		$11.3M Buy
3,307,429
+413,400
+14% +$1.03M 0.02% 994
2025
Q1 		$6.45M Buy
2,894,029
+407,136
+16% +$1.17M 0.01% 1266
2024
Q4 		$7.29M Sell
2,486,893
-459,810
-16% -$1.28M 0.01% 1201
2024
Q3 		$7.66M Buy
2,946,703
+1,218,100
+70% +$3.38M 0.01% 1183
2024
Q2 		$5.12M Buy
1,728,603
+239,000
+16% +$904K 0.01% 1282
2024
Q1 		$6.75M Buy
1,489,603
+30,100
+2% +$154K 0.01% 1220
2023
Q4 		$8.33M Sell
1,459,503
-232,550
-14% -$1.08M 0.01% 1039
2023
Q3 		$7.78M Sell
1,692,053
-844,550
-33% -$5.14M 0.01% 1067
2023
Q2 		$16.4M Sell
2,536,603
-274,900
-10% -$1.88M 0.02% 769
2023
Q1 		$21.2M Buy
2,811,503
+689,100
+32% +$6.26M 0.03% 679
2022
Q4 		$21.5M Sell
2,122,403
-858,400
-29% -$9.92M 0.03% 676
2022
Q3 		$29.5M Sell
2,980,803
-1,055,500
-26% -$11.6M 0.04% 497
2022
Q2 		$43M Buy
4,036,303
+1,418,700
+54% +$12M 0.05% 404
2022
Q1 		$25.5M Buy
2,617,603
+2,078,400
+385% +$19.7M 0.03% 631
2021
Q4 		$7.71M Buy
539,203
+454,903
+540% +$6.9M 0.01% 1217
2021
Q3 		$1.69M Sell
84,300
-318,900
-79% -$5.64M ﹤0.01% 2219
2021
Q2 		$8.87M Buy
+403,200
New +$11.1M 0.01% 1261

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jim Simons's ABCL Position: Q1 2026 in Review

Jim Simons reduced its AbCellera Biologics (ABCL) stake by 37% in Q1 2026, selling an estimated $3.16M and leaving 1,510,629 shares worth $5.27M. The position accounts for 0.01% of the portfolio, ranked #1350.

Jim Simons first reported a position in ABCL in Q2 2021 and has held it in 20 quarters since. The position peaked at $43M in Q2 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Jim Simons held 1,510,629 shares of AbCellera Biologics worth $5.27M as of Q1 2026.
  • Jim Simons sold 878,600 AbCellera Biologics shares in Q1 2026, an estimated $3.16M.
  • AbCellera Biologics made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1350 holding.
  • Jim Simons first reported a position in AbCellera Biologics in Q2 2021 and has held it in 20 quarters since.
  • Jim Simons's AbCellera Biologics position peaked at $43M in Q2 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.